

August 29, 2024

Contents

Clinical Profile Documentation 2
 AJCC Version 8 Staging..... 2
Problems..... 3
 Additions..... 3
Lab Analytes & Panels 3
 Additions..... 3
Medications 5
 Additions..... 5
 Updates 5
Regimen Library..... 6
 Additions..... 6
 Updates 6
 Renames 7
Billing & HCPCS Codes 8
 Updates 8
NDC – HCPCS Crosswalk 8
 Additions..... 8

Clinical Profile Documentation

AJCC Version 8 Staging

This release contains updated **TNM** values, **Staging Groups**, and **Template** functionality to align with AJCC version 8 conditions for:

- **Sarcoma of soft tissue, Malignant neoplasm of connective tissue**

Users will see updated values and descriptions for **Primary Tumor Type (T)**, **Regional Lymph Nodes (N)**, and **Distance Metastasis (M)**, documentation points for **Sarcoma, Soft Tissue**.

The following value is no longer available:

- **T1a, T1b, T2a, T2b**
- **Nx**
- **M0, M1**

The following documentation points now have updated descriptions:

- **T1, T2, T3, T4**
- **N0, N1**
- **cM0, cM1, pM1**

The staging calculator will display updated **Stage** values based on the changes to the staging groups. The added content does not affect previous charting documented on existing patients. A summary table is provided below.

All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

Tumor Type	Node	Metastasis	Stage
		cM1	IV
		pM1	IV
T4	N1	cM0	III
T4	N0	cM0	III
T3	N1	cM0	III
T3	N0	cM0	III
T2	N1	cM0	III
T2	N0	cM0	II
T1	N1	cM0	III
T1	N0	cM0	I

T0	NX	cM0	Unknown
T1	NX	cM0	Unknown
T2	NX	cM0	Unknown
T3	NX	cM0	Unknown
TX	N0	cM0	Unknown
TX	N1	cM0	Unknown
TX	NX	cM0	Unknown
T0	N1	cM0	Unknown
T0	N0	cM0	Unknown

Problems

Additions

Added items are available for documentation in **Problems** and appear in the **Charge Capture Report (CCR)**. Additional ICD-10 codes* may be displayed to present the surrounding nodes.

Lab Analytes & Panels

Additions

- ADAMTS13 inhibitor titer, BU
- ADAMTS13 profile interpretation
- ADAMTS13 profile interpretation (reflex test) panel
- Alb/Creat ratio, mg/g creat
- Alpha-Globin common test panel
- Altera panel
- BCR-ABL1 kinase domain mutation analysis
- BCR/ABL, tyrosine kinase inhib resist, mutation screen panel
- BCRABL fusion (210, 190, 205, 230)
- CLL/MCL prognosis: IgHV mutation analysis by NGS panel
- Coccid.Ag specimen type
- Coccidioides Ag interpretation
- Coccidioides Ag quant, ng/mL
- Copeptin proAVP panel
- Copeptin proAVP, pmol/L
- CSF aerobic/anaerobic culture, reflex to PCR (lumbar puncture only)
- CSF aerobic/anaerobic culture, reflex to PCR (lumbar puncture only) panel
- Eosinophils, smear, urine

- Haystack MRD(TM) baseline blood received date
- Haystack MRD(TM) baseline date of diagnosis
- Haystack MRD(TM) baseline EDTA blood collection date
- Haystack MRD(TM) baseline hospital discharge date
- Haystack MRD(TM) baseline location of specimen
- Haystack MRD(TM) baseline minimal residual disease
- Haystack MRD(TM) baseline MRD blood collection date
- Haystack MRD(TM) baseline next steps
- Haystack MRD(TM) baseline panel
- Haystack MRD(TM) baseline prism order ID
- Haystack MRD(TM) baseline recorded diagnosis
- Haystack MRD(TM) baseline report ID
- Haystack MRD(TM) baseline result details
- Haystack MRD(TM) baseline specimen location fax
- Haystack MRD(TM) baseline specimen location phone
- Haystack MRD(TM) baseline surgery date
- Haystack MRD(TM) baseline tumor collection date
- Haystack MRD(TM) baseline tumor received date
- Haystack MRD(TM) baseline tumor source
- Haystack MRD(TM) baseline tumor specimen ID
- Haystack MRD(TM) monitoring panel
- Herpes virus 6 DNA PCR, qn, log copies/mL
- Herpesvirus 7 DNA, qn real time, log copies/mL
- IHC single ab with interpretation panel
- Immediate PT mix panel
- Immediate PT mix, sec
- Invitae hereditary thrombophilia panel
- Onkosight advanced 523 gene NGS with pierianDx interpretation panel
- Paraneoplastic autoantibody evaluation panel, CSF
- PCA-2, CSF
- PDGFRA sequencing interpretation summary
- PDGFRA sequencing methods
- PDGFRA sequencing panel
- PDGFRA sequencing references 1
- PDGFRA sequencing report footer
- PDGFRA sequencing result
- Potassium, urine, 24 hour panel
- Protein/creatinine ratio, urine, mg/mg creat
- Signatera + Altera panel
- Signatera initial panel
- Signatera subsequent panel
- Susceptibility AFB, slow grower
- Tempus xM (NeXT Personal Dx) KIT panel
- Tempus xM KIT panel

Medications

Additions

- AB521 invest Oral
- Biest Topical Cream
- BNT327 invest IV
- DS-7300A invest IV
- FID-007 invest IV
- Hyaluronic Acid Vaginal Cream
- IBRX-042 invest subcutaneous
- IDE196 invest Oral
- MRTX0902 invest Oral
- Testosterone Sublingual
- TL118 invest Oral
- TORL-2-307-ADC invest IV

Updates

Medication	Update
BI 1810632 invest Oral	Added new name Zongertinib invest
Crovalimab-akkz IV	<ul style="list-style-type: none"> • Updated sigs and instructions • Changed default form • Added maximum single dose
Crovalimab-akkz Subcutaneous	<ul style="list-style-type: none"> • Updated sigs and instructions • Changed default form • Added maximum single dose
Donanemab-azbt IV	<ul style="list-style-type: none"> • Updated sigs and instructions • Changed default form
Infliximab IV (Remicade)	Added new sig options
Infliximab-axxq IV (Avsola)	Added new sig options
Infliximab-abda IV (Renflexis)	Added new sig options
Infliximab-dyyb IV (Inflectra)	Added new sig options
Pemetrexed IV	Added maximum single dose
SGN-B6A invest IV	Added new sig; 1.8 mg/kg AIBW intravenously once
Sodium Hyaluronate Vaginal	Added brand Revaree and Revaree Plus
STP938 invest IV	Added new name Dencatistat invest

Regimen Library

Topical Diclofenac for HFS Prevention in Capecitabine Regimens

To improve ease of ordering and serve as a reminder for prescribers, the Collaborative Care Committee (CCC) voted to add and precheck a **topical diclofenac prescription** for hand-foot syndrome (HFS) prevention in **capecitabine-containing regimens**. All regimens will be updated with the August content release.

Additions

Regimen Name	Diagnosis
Crovalimab-akkz IV D1 fb SQ D2,8,15,22 fb Q28D (PNH)	Paroxysmal Nocturnal Hemoglobinuria
Donanemab-azbt Q28D	Alzheimer's disease
Epcoritamab-bysp (Epkiny) SQ D1,8,15,22 fb D1,15 fb D1 Q28D (FL)	Lymphoma, Non-Hodgkin (NHL) (Parent)
Exemestane Q30D (Ovarian, Uterine)	Ovarian and Primary Peritoneal Cancer; Fallopian Tube Cancer; Uterine Cancer (Parent)
Ifosfamide Bolus D1-5 Q21D (Uterine Sarcoma)	Uterine Cancer (Parent)
Leuprolide Q28D (Ovarian, Uterine)	Fallopian Tube Cancer, Ovarian and Primary Peritoneal Cancer, Uterine Cancer (Parent)
Methotrexate HD + Rituximab IV D3 + Temozolomide PO Q14D (Induction)	Brain Tumor (Parent)
Venetoclax D1-14 + Azacitidine D1-7 Q28D (MDS)	Myelodysplastic Syndrome (MDS)
Vorasidenib Q30D	Brain Tumor (Parent)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference updates, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Amyloidosis
- Anal Cancer (Parent)
- Arthritis, Rheumatoid

- Bile Duct Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gallbladder Cancer
- Gastric Cancer
- Hepatocellular Carcinoma (HCC)
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Skin
- Multiple Myeloma (MM)
- Neuroendocrine Tumor, Carcinoid (Parent)
- Ovarian and Primary Peritoneal Cancer
- Pancreatic Cancer
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Renal Pelvis and Ureter Cancer
- Renal Cell Carcinoma (RCC)
- Sarcoma, Soft Tissue (Parent)
- Thyroid Cancer (Parent)
- Urethral Cancer
- Uterine Cancer (Parent)

Renames

Previous Name	New Name
Daratumumab SQ Q7D (Part 1 of 3)	Daratumumab SQ C1-2 D1,8,15,22 fb C3-6 D1,15 fb C7-12 D1 Q28D
Doxorubicin 60 mg/m ² CIV D1-3 + Ifosfamide 1500 mg/m ² D1-4 Q21D (Uterine Sarcoma)	Doxorubicin 25 mg/m ² D1-3 + Ifosfamide 3000 mg/m ² CIV D1-3 Q21D (Uterine Sarcoma)
Epcoritamab-bysp SQ D1,8,15,22 fb D1,15 fb D1 Q28D	Epcoritamab-bysp (Epkiny) SQ D1,8,15,22 fb D1,15 fb D1 Q28D (DLBCL)
Fulvestrant Q28D (Breast)	Fulvestrant Q28D (Breast, Uterine Sarcoma)

Billing & HCPCS Codes

Updates

Medication	HCPCS Codes
Adalimumab-ryvk Subcutaneous Auto-Injector	J3590 per 40 mg
Adalimumab-ryvk Subcutaneous	J3590 per 40 mg
Afamitresgene autoleucel IV	J9999 per 10 x 10e9 MAGE-A4 TCR pos T cells
Crovalimab-akkz IV	J3590 per 340 mg
Crovalimab-akkz Subcutaneous	J3590 per 340 mg
Donanemab-azbt IV	J0175 per 2 mg

NDC – HCPCS Crosswalk

Additions

Effective July 1, 2024.

Medication (Brand)	HCPCS Code	NDC
Cyclophosphamide IV	J9073 per 5 mg	<ul style="list-style-type: none"> 75907-0191-02 75907-0190-07 75907-0189-35